CI-960, a new fluoroquinolone, for therapy of experimental ciprofloxacin-susceptible and -resistant Staphylococcus aureus endocarditis.
CI-960 is a new fluoroquinolone with enhanced in vitro activity against gram-positive pathogens. The efficacy of the drug was compared with that of vancomycin by using the rabbit model of nafcillin- and ciprofloxacin-susceptible and -resistant Staphylococcus aureus endocarditis. Animals received int...
Gardado en:
| Publicado en: | Antimicrob Agents Chemother |
|---|---|
| Principais autores: | , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
American Society for Microbiology (ASM)
1992
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.govhttps://pmc.ncbi.nlm.nih.gov/articles/PMC190313/ https://ncbi.nlm.nih.govhttps://pubmed.ncbi.nlm.nih.gov/1329613/ https://ncbi.nlm.nih.govhttps://doi.org/10.1128/aac.36.6.1192 |
| Tags: |
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|